Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 1.1.98.3 - decaprenylphospho-beta-D-ribofuranose 2-dehydrogenase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Infections
Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 inhibitors TBA-7371, PBTZ169 and OPC-167832.
In Vivo Activity of the Benzothiazinones PBTZ169 and BTZ043 against Nocardia brasiliensis.
Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-?-d-Ribose Oxidase (DprE1) Inhibitors.
Mycetoma
In Vivo Activity of the Benzothiazinones PBTZ169 and BTZ043 against Nocardia brasiliensis.
Tuberculosis
2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1.
A Simple Work-Up-free, Solvent-free Approach to Novel Amino Acid Linked 1,4-Disubstituted 1,2,3-Triazoles as Potent Antituberculosis Agents.
Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo.
Benzothiazinones mediate killing of Corynebacterineae by blocking decaprenyl phosphate recycling involved in cell wall biosynthesis.
Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-?-D-ribose 2'-epimerase DprE1 of Mycobacterium tuberculosis.
Characterization of DprE1-mediated benzothiazinone resistance in Mycobacterium tuberculosis.
Chemical Space Exploration of DprE1 Inhibitors Using Chemoinformatics and Artificial Intelligence.
Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones.
Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 inhibitors TBA-7371, PBTZ169 and OPC-167832.
Crystal structure of decaprenylphosphoryl-?- D-ribose 2'-epimerase from Mycobacterium smegmatis.
Determinants of the Inhibition of DprE1 and CYP2C9 by Antitubercular Thiophenes.
Discovery of Novel Thiophene-arylamide Derivatives as DprE1 Inhibitors with Potent Antimycobacterial Activities.
DprE1 - from the Discovery to the Promising Tuberculosis Drug Target.
DprE1 Is a Vulnerable Tuberculosis Drug Target Due to Its Cell Wall Localization.
DprE1, a New Taxonomic Marker in Mycobacteria.
Exploring the Potential Inhibition of Candidate Drug Molecules for Clinical Investigation based on their Docking or Crystallographic Analyses against M. tuberculosis Enzyme Targets.
Fluorescent Benzothiazinone Analogues Efficiently and Selectively Label Dpre1 in Mycobacteria and Actinobacteria.
Identification of a pyrimidinetrione derivative as the potent DprE1 inhibitor by structure-based virtual ligand screening.
In silico guided design of non-covalent inhibitors of DprE1: synthesis and biological evaluation.
In vitro and in vivo antimicrobial activities of a novel piperazine-containing benzothiazinones candidate TZY-5-84 against Mycobacterium tuberculosis.
In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis.
Novel insight into the reaction of nitro, nitroso and hydroxylamino benzothiazinones and of benzoxacinones with Mycobacterium tuberculosis DprE1.
Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis.
Pseudomonas aeruginosa D-Arabinofuranose Biosynthetic Pathway and Its Role in Type IV Pilus Assembly.
Scaffold Morphing To Identify Novel DprE1 Inhibitors with Antimycobacterial Activity.
Structural and inhibition analysis of novel sulfur-rich 2-mercaptobenzothiazole and 1,2,3-triazole ligands against Mycobacterium tuberculosis DprE1 enzyme.
Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors.
Structural studies of Mycobacterium tuberculosis DprE1 interacting with its inhibitors.
Structure based pharmacophore modelling approach for the design of azaindole derivatives as DprE1 inhibitors for tuberculosis.
Structure, dynamics, and interaction of Mycobacterium tuberculosis (Mtb) DprE1 and DprE2 examined by molecular modeling, simulation, and electrostatic studies.
Structure-Based Drug Design and Characterization of Sulfonyl-Piperazine Benzothiazinone Inhibitors of DprE1 from Mycobacterium tuberculosis.
The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium tuberculosis.
The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis.
The frequently occurring components of essential oils beta elemene and R-limonene alter expression of dprE1 and clgR genes of Mycobacterium tuberculosis H37Ra.
Towards a new combination therapy for tuberculosis with next generation benzothiazinones.
Virtual screening and free energy estimation for identifying Mycobacterium tuberculosis flavoenzyme DprE1 inhibitors.